Home › Oropharyngeal Cancer › Maryland › Baltimore
Oropharyngeal Cancer clinical trials in Baltimore, MD
4 studies for Oropharyngeal Cancer are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RecruitingPhase 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Greater Baltimore Medical Center, Baltimore
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
RecruitingPhase 2
- Johns Hopkins Hospital East Baltimore, Baltimore
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RecruitingPhase 2
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · 9 mi away
- and 1 more
Oropharyngeal Cancer trials in other cities
- Atlanta, GA8 studies
- Edison, NJ8 studies
- Chicago, IL7 studies
- New York City, NY6 studies
- Queens, NY5 studies
- St. Louis, MO5 studies
- Tampa, FL5 studies
- Kansas City, MO5 studies
- Philadelphia, PA5 studies
- Milwaukee, WI5 studies
- Omaha, NE5 studies
- Pittsburgh, PA5 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Pancreatic Cancer31 studies
- Colorectal Cancer31 studies
- Metastatic Cancer28 studies
- Obesity26 studies
- Bladder Cancer24 studies
- Heart Failure24 studies
- Ovarian Cancer22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.